Oncogenic RBM19 modulated by MAX-mediated allelic transcription regulation in hepatocellular carcinoma progression
Archives of Biochemistry and Biophysics · 2025
DOI: 10.1016/j.abb.2025.110576 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2025. Verfasst von Yanxiu Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Provincial Key Laboratory of Precision Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical Univ…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, RNA-Binding Proteins, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, NSFC, Taishan Scholar Foundation of Shandong Province.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC), the most common type of liver cancer, exhibits the highest incidence in Asia and Africa. However, the mechanisms underlying the malignant transformation of normal cells to HCC cells remain poorly understood. MYC-associated protein X (MAX) functions as an oncogenic transcription factor (TF) in HCC by binding to E-box elements in promoters or enhancers of target gene. Using our previously developed Updated Integrative Functional Genomics Approach (TUIFGA), we identified 248 single nucleotide polymorphisms (SNPs) within MAX-binding sites in HCC cells. Among these SNPs, rs2290798 in the RBM19 promoter was significantly associated with HBV-related HCC risk. Functional assays indicated that the rs2290798 genetic variant could disrupt TF MAX binding to the RBM19 promoter and downregulate RBM19 expression. RBM19 acts as an oncogenic RNA-binding protein (RBP) through promoting proliferation, migration, and invasion of HCC cells. Indeed, RBM19 functions as a RBP via stabilizing several oncogenic transcripts (C1QTNF6, GLS1, MALAT1 or RBM19) and elevating their expression levels in HCC. These findings highlight the curial role of RBM19 in HCC progression and its potential as a therapeutic target in cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shandong Provincial Key Laboratory of Precision Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shando…
- School of Life Sciences, Shandong First Medical University and Shandong Academy of Medical Sciences, Taian, 271021, Shandong Province, China.
- Shandong University Cancer Center, Jinan, Shandong Province, 250117, China.
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, 250117, Shandong Province, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Canc…
Förderung
- Natural Science Foundation of Shandong Province
- NSFC
- Taishan Scholar Foundation of Shandong Province
Zitieren
APA
Zheng, Y., Yin, X., Han, L., Liu, S., Zhang, N., Yang, Y., & Yang, M. (2025). Oncogenic RBM19 modulated by MAX-mediated allelic transcription regulation in hepatocellular carcinoma progression. Archives of Biochemistry and Biophysics. https://doi.org/10.1016/j.abb.2025.110576
Vancouver
Zheng Y, Yin X, Han L, Liu S, Zhang N, Yang Y, et al. Oncogenic RBM19 modulated by MAX-mediated allelic transcription regulation in hepatocellular carcinoma progression. Archives of Biochemistry and Biophysics. 2025. doi:10.1016/j.abb.2025.110576
BibTeX
@article{Zheng2025,
author = {Zheng, Yanxiu and Yin, Xiaolei and Han, Linyu and Liu, Shuqing and Zhang, Nasha and Yang, Yanting and Yang, Ming},
title = {Oncogenic RBM19 modulated by MAX-mediated allelic transcription regulation in hepatocellular carcinoma progression},
journal = {Archives of Biochemistry and Biophysics},
year = {2025},
doi = {10.1016/j.abb.2025.110576}
}
EUVIMED